India, Aug. 20 -- Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.
The company's stock is currently trading at $47.61, down 5.34 percent, over the previous close of $50.29 on the Nasdaq. It has traded between $15.86 and $50.81 in the past one year.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
In a related equity investment agreement, UroGen will invest up to $7 million in the equity securities of IntraGel to support the Phase 2 clinical development of TumoCure, IntraGel's investigational therapy for advanced head a...